SEC Comment Letter 0000000000-24-001681 to Kura Oncology, Inc. (KURA) (CIK 0001422143) (KURA)
Kura Oncology, Inc. (KURA) (CIK 0001422143)
Date: Feb. 29, 2024 · CIK: 0001422143 · Accession: 0000000000-24-001681
AI Filing Summary & Sentiment
File numbers found in text: 333-276995
Letter
United States securities and exchange commission logo February 12, 2024 Troy Wilson, Ph.D., J.D. President and Chief Executive Officer Kura Oncology, Inc. 12730 High Bluff Drive, Suite 400 San Diego, CA 92130 Re:Kura Oncology, Inc. Registration Statement on Form S-3 Filed February 9, 2024 File No. 333-276995 Dear Troy Wilson: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Wade Andrews, Esq.
Show Raw Text
United States securities and exchange commission logo
February 12, 2024
Troy Wilson, Ph.D., J.D.
President and Chief Executive Officer
Kura Oncology, Inc.
12730 High Bluff Drive, Suite 400
San Diego, CA 92130
Re:Kura Oncology, Inc.
Registration Statement on Form S-3
Filed February 9, 2024
File No. 333-276995
Dear Troy Wilson:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Wade Andrews, Esq.